329 Figure 2 (A-I) | Serum concentrations and ratios of type I (C1M), III (C3M, PRO-C3, C3M/PRO-C3), IV (C4M, PRO-C4, C4G, PRO-C4/C4M) and VI (C6Ma3) collagen formation and degradation biomarkers in patients with CD (n=101), stratified by disease behavior, and in healthy controls (HC, n=96). (A-C) Serum C3M levels were significantly elevated in patients with CD compared to HC, indicating relatively increased degradation of type III collagen, whereas PRO-C3 levels were equal among groups, resulting in a moderately elevated C3M/PRO-C3 ratio in patients with CD compared to controls (especially in patients with nonstricturing, non-penetrating disease), which was however only nominally statistically significant. (D-F) Serum PRO-C4 and C4M levels were elevated in patients with CD compared to HC, but the PRO-C4/C4M ratio was nominally significantly elevated in patients with stricturing disease, compared to patients with non-stricturing, non-penetrating disease. (G) A specific fragment of MMP-2,9,13-mediated type I collagen degradation (C1M) was markedly elevated in patients with CD compared to HC. (H) Serum C4G levels were nominally significantly elevated in patients with CD, particularly in patients with penetrating CD, compared to HC. (I) Serum C6Ma3 levels were elevated in patients with CD compared to HC. Boxplots were drawn according to the Tukey method, with inner fences defined as 25th/75th percentile ±1.5 IQR. Significances were calculated from Kruskal-Wallis tests with post-hoc Bonferroni correction for multiple comparisons. *P<0.05; **P<0.01; ***P<0.001. #Only nominally significant, but not statistically significant after Bonferroni correction for multiple comparisons. Collagen biomarkers and Crohn’s disease behavior
RkJQdWJsaXNoZXIy MjY0ODMw